ECOG-ACRIN EAY131

Clinical Trial Title NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Trial Status Closed to Enrollment
Start Date 08/11/2016
Location Doctors & Locations
Trial Type Cancer - Adult Oncology
Specific Condition Solid Tumors or Lymphomas
Description This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Eligibility Criteria

Eligibility Criteria for Screening Biopsy

  • ≥ 18 years of age .
  • Must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and meet one of the following criteria: Patients must have progressed following at least one line of standard systemic therapy and there must not be other approved/standard therapy available that has been shown to prolong overall survival OR Patients for whose disease no standard treatment exists that has been shown to prolong overall survival.
  • ECOG performance status ≤ 1 and a life expectancy of at least 3 months.
  • Must not currently be receiving any other investigational agents.
  • Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy ≥ 4 weeks prior to start of treatment.
  • Must have discontinued steroids ≥ 1 week.

 There are other criteria must be met for receiving first treatment that are not listed.
IRB Number Central IRB
Notes https://clinicaltrials.gov/ct2/show/NCT02465060
Principal Investigator Jacqueline Vuky, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org